Cash and cash equivalents, as well as other financial assets, total $551.4 million as of December 31, 2025, compared to $710.3 million as of December 31, 2024. The decrease is mainly due to $234.9 million operational cash usage, principally as a result of ongoing research and development activities, as well as unrealized foreign exchange translational losses of $41.8 million, which do not impact the expected cash reach, partially offset by the net proceeds of the public offering of $117.9 million.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMTX:
- Immatics reports FY25 EPS (EUR 1.61) vs. EUR 0.14 last year
- Immatics price target raised to $25 from $23 at Mizuho
- Immatics’ treatment of Stage II and higher CM granted FDA orphan designation
- Immatics Publishes Updated PRAME-Focused Investor Presentation on January 12, 2026
- Immatics price target raised to $17 from $14 at BofA